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Abstract
Medicare Part D began coverage of prescription drugs in 2006. Rather than setting pharmaceutical prices, the
government contracted with private insurers to provide drug coverage. Theory suggests that additional
insured consumers will raise the optimal price of a branded drug, while the insurer's ability to move demand
to substitute treatments may lower prices. We estimate the program's effect on the price and utilization of
pharmaceutical treatments. We find that Part D enrollees paid substantially lower prices than while uninsured,
and increased their utilization of prescription drugs. We find relative price declines only for drugs with
significant therapeutic competition.
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Prescription drug expenditures represent the most rapidly growing component of health care 
spending, increasing from 5 percent of health care spending in 1980 to more than 10 percent by 
2005 (Centers for Medicare and Medicaid Services (CMS) 2007a). Further, almost 60 percent of 
all prescriptions in the United States are filled for beneficiaries of Medicare, Medicaid, and other 
government programs. Rapid innovation in new pharmaceuticals has contributed substantially to 
quality of life and longevity in the US (Frank Lichtenberg 1996). These facts, combined, indicate 
that government procurement schemes are critical both in determining government expenditure 
on pharmaceuticals and in stimulating innovation of new treatments.
In this paper, we show that the institutions and mechanisms used by the government to pur-
chase prescription drugs can strongly affect market outcomes. By institutions, we have in mind 
large buyer groups, structured incentives for patients to consume certain products, and the devel-
opment and use of formularies. A formulary is a mechanism that allows a buyer to identify a 
therapeutically similar treatment as a viable substitute for a patented treatment, and to create 
price competition due to the ability to substitute away from the more expensive product. When 
bargaining with the seller of a patented product, the ability to shift demand to a substitute drug 
is a powerful negotiating tool.
Our paper provides evidence for what we consider a surprising outcome: in the case of the 
new prescription drug program for Medicare enrollees, moving consumers from cash-paying 
status to membership in an insured group lowers optimal prices for branded prescription drugs 
below what they otherwise would be. This is surprising because the standard effect of insurance 
is to create inelastic demand and therefore elicit higher prices from a seller with market power 
(Duggan and Scott Morton 2006). However, the insurers that we study bundle insurance with 
a formulary and other mechanisms to create elastic demand. An individual consumer typically 
does not know which drugs are acceptable therapeutic substitutes; the consumer’s physician typi-
cally has poor knowledge of prices, especially negotiated prices; and any one consumer is too 
small a share of demand to negotiate with a pharmaceutical company. A prescription drug plan 
can potentially surmount all three hurdles.
Our evidence leads us to conclude that the formulary and other mechanisms perform the spe-
cial role of allowing buyers to move market share among drugs with patent protection, thereby 
raising cross-price elasticities and lowering purchase prices (or reducing price increases) for 
branded drugs. This result contrasts with the common intuition that an uninsured consumer, 
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paying at the margin for her own purchases, is the best tool with which to create competition 
in the market and impose pricing discipline on sellers. Certainly, this reasoning is at least part 
of the rationale behind many current policies in health care such as tax-free health care savings 
accounts (R. Glenn Hubbard, John F. Cogan, and Daniel P. Kessler 2005). Our evidence suggests 
that this picture is incomplete; for maximum effect, the consumer also needs to be part of a group 
that can substitute one provider for another.
Our setting is the recent significant increase in government intervention in the pharmaceutical 
industry represented by Medicare Part D. For the first 40 years of its existence after its creation in 
1965, the Medicare program provided virtually no coverage for beneficiaries’ prescription drug 
costs outside of treatments such as cancer drugs administered in a doctor’s office or hospital. But 
as prescription drug expenditures increased much more rapidly than other health care spending 
in recent years, the political pressure built for Medicare to cover prescription drugs. In December 
2003, the Medicare Prescription Drug Improvement and Modernization Act created Medicare 
Part D, which would begin providing coverage for prescription drug costs in January of 2006 for 
those Medicare recipients who chose to enroll.
Part D is the largest expansion of Medicare since the program’s inception and has been pro-
jected to cost $780 billion over its first ten years (2006–2015).1 This feature alone made the 
program controversial at the outset. Not only is Part D a very large entitlement program, it 
significantly expands the role of the government as a buyer of prescription pharmaceuticals. 
Governments outside the United States use their power as large buyers to pay relatively low 
prices for new, patent-protected medications. In contrast, Part D is set up so that the government 
does not directly purchase drugs, but rather subsidizes participating private prescription drug 
plans, which then negotiate with pharmaceutical companies over drug prices.
Part D can also be contrasted to Parts A and B of Medicare, in which the CMS sets prices for 
each covered service and reimburses providers directly per service.2 In Part D, CMS pays the 
participating plan a lump sum per enrollee and has no control over the prices paid to pharmaceu-
tical manufacturers by the plan or the prices charged to enrollees by the plan. Instead, the legis-
lation creates competition among plans for the business of enrollees, which is intended to drive 
drug prices and premiums to competitive levels. Each Medicare recipient can choose between 
the plans offered in her area based on the drugs covered, the prices of those drugs, the monthly 
premium, and other plan parameters.
In the empirical work below, we investigate the effect of Medicare Part D on the price and uti-
lization of branded pharmaceutical treatments. Theoretically, the program could either increase 
or decrease prices paid to pharmaceutical companies. On the one hand, once enrolled in Part D, 
enrollees who had previously been uninsured would have a lower elasticity of demand than before, 
leading to an increase in the manufacturers’ profit-maximizing prices for drugs with market pow-
er.3 On the other hand, Part D plans could exclude certain treatments from their formulary or steer 
their enrollees away from certain treatments in response to the prices of those treatments, which 
a cash-paying individual could not typically do on her own. This could give these plans a strong 
lever with which to negotiate price reductions from pharmaceutical manufacturers. We are also 
interested in the effect of the program on utilization.4 In addition to any ex-manufacturer price 
effect, the insurance provided by Part D would lower beneficiaries’ out-of-pocket prices, and 
therefore affect utilization (Teresa Gibson, Ronald Ozminkowski, and Ron Goetzel 2005).
1 See the “Medicare Trustees Report,” http://www.cms.hhs.gov/reportstrustfunds/downloads/tr2006.pdf.
2 Hospital inpatient reimbursement in Part A depends both on the patient’s diagnosis and on the treatment.
3 See Nina Pavcnik (2002) for evidence on the effect of cost sharing on firms’ profit-maximizing prices.
4 Recent research by Wesley Yin et al. (2008) and Lichtenberg and Shawn Sun (2007) suggests that Part D did 
increase utilization, although the authors of both studies utilize data from just one pharmacy chain to estimate this.
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Our estimation strategy exploits variation across branded drugs in their pre-Part D Medicare 
market shares to estimate the effects of Part D on pharmaceutical prices and utilization. Our 
first set of results strongly suggests that Medicare Part D led to a substantial relative decline in 
average branded pharmaceutical prices. In other words, though branded prescription drug prices 
trend upward from 2003 to 2006, brands with high sales to consumers eligible for Medicare Part 
D experienced significantly lower average price increases than other brands.
Additionally, our estimates reveal that the effect is driven by the consumption of drugs by 
Medicare recipients without insurance before part d. It appears to be the movement of Medicare 
recipients from cash-paying uninsured status to insured under a plan that causes the relative 
decline in per unit prices. The most plausible mechanism driving this result is not the insurance 
per se, but the activities of the insurer.
However, for therapeutic classes with just one or two brands, plans would not be able to move 
market share to therapeutic substitutes because legislation required them to cover all drugs in 
small classes. Consistent with this prediction, our analyses show that prices do not decline in 
relative terms for brands with zero or only one substitute in a class.
Combining our results with the mechanical effect of Part D on out-of-pocket prices, we expect 
that the average cost of prescription drugs for an uninsured Medicare recipient with average 
prescription drug spending fell substantially. In light of this, it is not surprising that our results 
suggest a substantial increase in utilization among Medicare-intensive drugs, although our esti-
mated coefficients for utilization are not precisely estimated.
Our findings come with an important caveat: we analyze only the first year of Part D. This is 
a complex program in which both regulators and firms are learning over time and coping with 
moral hazard, adverse selection, technological change, and political pressure. It is plausible, for 
example, that pharmaceutical manufacturers have not yet fully adjusted to the policy change, and 
thus more work is clearly warranted to estimate the medium- and-long term effect of the program.
The outline of the paper is as follows. In the next section, we provide background on the 
Medicare program and on key features of Part D and discuss the effect of Part D on pharmaceu-
tical firms’ profit-maximizing prices. Section II describes our data and the construction of our 
sample of drugs. In the following two sections we specify our empirical framework, summarize 
our main results, and describe how our estimates vary across therapeutic categories. The final 
section concludes.
I.  Background on, and Incentive Effects of, Medicare Part D
A. institutional Background
While there are several components to the Medicare Prescription Drug Improvement and 
Modernization Act (MMA), the most important is the creation of Medicare Part D, which pro-
vides insurance coverage for prescription drug costs to Medicare recipients who voluntarily 
enrolled in the program beginning in January of 2006. This legislation also created the Medicare 
Discount Drug Card Program, which took effect in early 2004 and was designed to help Medicare 
recipients receive discounts on their prescriptions during the two-year window prior to the com-
mencement of Part D.
In contrast to Parts A and B of the program, Part D benefits are provided through one of two 
types of private insurance plans.5 The first type, known as a Prescription Drug Plan (PDP), 
provides coverage only for prescription drug costs, while Medicare Advantage Plans (MA-PD) 
5 For a detailed discussion, please see Duggan, Patrick Healy, and Scott Morton (2008).
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insure all Medicare-covered services, including hospital care, physician services, and prescrip-
tion drugs.6
A plan “sponsor” contracts with CMS to offer a plan in one (or more) of the 34 defined regions 
of the United States. Plans are allowed to have a formulary that excludes certain drugs from cov-
erage, though they are required to have at least two drugs on the formulary for each therapeutic 
class.7 Furthermore, a plan cannot exclude treatments from any of six protected classes (e.g., HIV 
antiretrovirals, cancer drugs) from the formulary. The actuarial value of the benefits offered by 
a plan must be at least as generous as those specified in the 2003 MMA legislation. In the 2006 
calendar year this included a deductible of $250, a 25 percent co-pay for the next $2,000 in 
spending, no coverage for the next $2,850 (this is often referred to as the “doughnut hole”), and a 
5 percent co-pay once out-of-pocket expenditures reach $3,600. These figures change annually. 
Plans are financed through a combination of enrollee monthly premiums and subsidies from the 
federal government.
To enroll in Part D, a Medicare recipient can choose among those plans offered in her region 
of the country. When making this choice, the recipient would consider the plan’s monthly pre-
mium, the drugs included on the formulary, the prices of those drugs, and service quality.8 Dual 
eligibles, who are Medicare recipients also enrolled in the means-tested Medicaid program, were 
required to enroll in a Part D plan, although their premiums, co-pays, and deductibles were 
heavily subsidized by the government. In January of 2007, approximately 36 percent of the 17.3 
million PDP enrollees were automatically enrolled in a PDP because they were also on Medicaid 
(6.3 million) and an additional 13 percent of enrollees (2.2 million) were eligible for low-income 
subsidies that reduce out-of-pocket costs.
B. part d’s impact on manufacturers’ incentives
Given the significance of the changes in insurance coverage described above, and the par-
ticular structure of drug procurement for this program, it seems plausible that Medicare Part D 
had an impact on prices and quantities in the pharmaceutical sector. To simplify the theoretical 
discussion, we assume that the market for Part D plans is perfectly competitive. In every region 
in the United States there are at least 27 plans competing for local Part D enrollees. While the 
market is more concentrated than this number would suggest,9 in this paper we will nevertheless 
abstract from the issue of whether plans have market power.
If plans are effectively not setting the market price for a patented brand, it is the brand’s manu-
facturer that is choosing prices before and after the Part D program. To fix ideas, suppose that 
all Medicare enrollees have no coverage prior to Part D and must pay cash for their prescription 
drugs, but then enroll in Part D when it begins. Notice that when this group paid cash for pre-
scription drugs, its members were not able to create effective price competition between drugs 
by threatening to switch to a therapeutic substitute. Once in Part D, however, these consumers 
were represented by a PDP. The result of the change in institutional structure is an increase in the 
cross-price elasticity of substitution for this group. For a number of common models of demand, 
as consumers’ elasticity of substitution rises, the optimal price for the drug falls.10 A second 
6 To reduce the likelihood that Part D would crowd out existing prescription drug coverage to retired workers by 
their former firms, CMS subsidized those firms that continued to provide this insurance. 
7 See Haiden Huskamp et al. (2003) for evidence on the effect of formularies on consumers’ utilization of pharma-
ceutical treatments. The findings suggest that formularies can substantially alter treatment patterns.
8 See Kosali Simon and Claudio Lucarelli (2006) for an examination of the determinants of plans’ monthly premiums.
9 The top three plans (UHC-Pacificare, Humana Inc., and Wellpoint, Inc.) accounted for 50 percent of Part D enroll-
ment in 2006 (Kaiser Family Foundation 2007).
10 For a specific model, please see Duggan and Scott Morton (2008).
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effect comes from the fact that the group is now subsidized at 75 percent of the cost of the drug in 
the main coverage region and at 95 percent in the catastrophic region.11 Sensitivity to price falls 
and this causes the optimal price to increase. In this setting, we see there are two effects working 
in opposite directions, and thus it is ultimately an empirical question that dominates.
Consumers with private insurance or those who continue to be uninsured do not experience 
these changes upon the implementation of Part D.12 If the average price that we measure in the 
data comprised sales to consumers who move from uninsured to Part D and consumers who 
experience no change in demand, we would see a change in the average price of brands that 
depends on the fraction of that drug purchased by cash-paying but Part D–eligible consumers, 
as well as the change in price those consumers pay. The empirical strategy of the paper is to use 
data on average price and the fraction of a drug’s sales to Part D–eligible consumers to back out 
the price changes caused by Part D.
There is one possible spillover between Part D and the private market that might cause pri-
vate price changes caused by Part D to be nonzero. When dual eligibles move from Medicaid to 
Medicare, they shift from purchasing through a fairly inelastic purchaser (the state) to a more 
elastic purchaser (the PDP).13 Because the inelastic Medicaid demand pays whatever market 
price is chosen by the manufacturer, a reduction in Medicaid demand might lower the optimal 
price for the brand in the private market (see Duggan and Scott Morton 2006). If a drug’s dual 
share is zero, this effect will not be present. We investigate this issue in our empirical analyses 
below.
According to Part D regulations, there are six “protected” therapeutic classes in which each 
PDP must be less aggressive with their formularies than in other classes.14 While a PDP cannot 
exclude any drug in a protected category, it can create financial incentives or administrative 
hurdles to affect a patient’s choice of drug. We do not know whether the restrictions applied to 
these classes have a measurable impact on the behavior of PDP because in the first year of the 
program it was not clear how much CMS would oversee formularies. If restrictions are binding, 
their effect will be to reduce Part D’s effect on the substitutability among drugs in these classes 
and therefore reduce the PDP’s ability to extract manufacturer discounts.
Similarly, CMS required that all PDPs include at least two drugs in each therapeutic class and 
at least one in each Formulary Key Drug Type (FKDT), which is a finer category than class. A 
class/FKDT with only one or two brands in it will create a challenge for any PDP bargaining 
for low prices. The CMS regulations limit the PDPs’ ability to substitute away from drugs in 
the class, and presumably the manufacturers of these drugs are aware of their market power. 
We expect that drugs in these two situations (protected or “small” categories) will have small or 
negligible changes in cross-price elasticities. We modify our specification to allow for different 
effects for drugs in this less competitive environment.
Taken together, we predict an ambiguous effect of Medicare Part D on average pharmaceuti-
cal prices, with the sign depending on whether the policy-induced reduction in the elasticity of 
demand more than offsets any plan-induced increase in substitutability across treatments. This 
latter effect should be less important for brands in one of the six protected therapeutic  categories 
and for those brands that are one of just one or two treatments in a class/FKDT. Furthermore, 
11 The subsidy depends on an enrollee’s total prescription drug expenditures. As expenditures rise, an enrollee 
moves from 100 percent (deductible), to 25 percent, to 100 percent (doughnut hole), to 5 percent (catastrophic region) 
cost sharing. 
12 Spillovers in negotiation from an insurer’s private plans to their Part D plans are prohibited by the legislation.
13 It is worth noting that many states were negotiating for supplemental rebates based on state-level Medicaid for-
mularies by 2005, so they are not completely unresponsive to price.
14 All products in the HIV, anticancer, anticonvulsant, immunosuppressant, antipsychotic, and antidepressant cat-
egories must be included in all Part D formularies.
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to the extent that Part D reduces Medicare recipients’ out-of-pocket costs, it should lead to an 
increase in overall utilization that is increasing in the drug’s Medicare market share. We investi-
gate these issues in the empirical analyses below.
II.  Data and Constructing the Analysis Sample
A. imS health
To estimate the impact of Medicare Part D on our outcome variables of interest, we begin by 
merging data from two sources. The first was obtained from IMS Health and contains data on 
total sales (excluding those to hospitals and long-term care) for all pharmaceutical products in 
the United States in each year from 2001 to 2006. The data also contain the number of standard-
ized units of the product that were sold and the average number of units per daily dose in each 
year. This allows us to calculate the average price per day and the number of daily doses in each 
year for each product.15 In calculating both prices and quantities, we aggregate sales for all ver-
sions of the same drug in each year.
B. medical Expenditure panel Survey
Our second main source of data is the Medical Expenditure Panel Survey (MEPS), a pub-
licly available dataset constructed annually by the Agency for Healthcare Research and Quality 
(AHRQ). In carrying out this survey, AHRQ collects data from a nationally representative sample 
of the civilian noninstitutionalized population residing in the United States and asks questions 
about prescriptions filled during the year, as well as demographic characteristics and insurance 
coverage. We use this dataset to calculate a brand’s Medicare Market Share (MMS), which is the 
proportion of its consumers enrolled in Medicare.
For each reported prescription, the Prescribed Medicines file lists the drug name, the total 
amount paid, the amount paid out of pocket and the amount paid by each of ten possible sources 
of insurance, a person-level identifier, and a person-level weight. In the 2003 MEPS data (the 
same year in which the Medicare Modernization Act was signed into law), there are 304,324 pre-
scriptions reported by 20,475 individuals. To increase our precision in measuring drug-specific 
Medicare market shares and related explanatory variables of interest, we utilize both the 2002 
and 2003 versions of the MEPS Prescribed Medicines file.16
Using the person-level identifier, this data on the utilization of prescription drugs can then be 
linked to the MEPS Full Year Consolidated Data File (CDF), which includes the person’s age 
and information about her health insurance coverage. One question summarized in the CDF 
portion of the survey asks whether the respondent was ever enrolled in Medicare during the 
2003 calendar year. The weighted fraction answering yes to this question is 14.4 percent, which 
is much greater among those age 65 and older (98.8 percent) than among the nonelderly (2.2 
percent). Because Medicare recipients have substantially greater utilization of prescription drugs 
than their counterparts not in the program, their fraction of prescriptions (40.3 percent) is almost 
three times greater than their share of the population.
The Prescribed Medicines file also has information on the source of payment for each pre-
scription. The first column of Table 1 summarizes this information for all prescriptions, while 
15 Note that the prices we use in our estimation are not the posted prices at the drugstore, but the revenues of each 
drug divided by units sold from invoice data.
16 This approximately doubles the number of prescriptions for the typical drug in our sample. The Medicare shares 
in 2002 and 2003 are very strongly correlated, with a correlation of 0.92.
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columns 2 and 3 differentiate between those with and without Medicare coverage, respectively. 
In 2003 Medicare recipients paid approximately 51 percent of the cost out of pocket, while 
those not on Medicare paid substantially less, at 41 percent. The table also reveals that Medicare 
recipients received much less coverage from private insurers in that year (20 versus 45 percent) 
but this was partially made up for by greater coverage from public insurance including Medicaid, 
the Department of Veterans Affairs, and Medicare.17
The variation across drugs in the fraction of individuals taking the drug who were eligible for 
Part D prior to its enactment (and subsequently may have enrolled in it) is critical to the iden-
tification strategy of the paper. According to the 2003 MEPS, this variation is substantial. For 
example, Zoloft, an antidepressant drug that is ranked fifth in terms of sales in the IMS data, 
has a Medicare market share of 27.1 percent. The corresponding value for Plavix, which is used 
primarily by those at risk of heart attack or stroke and was ranked sixteenth in terms of sales in 
that same year, is 72.9 percent.
C. Constructing the Analysis Sample
The MMA was signed into law on December 8, 2003. Medicare Part D did not begin opera-
tion, however, until more than two years later, in January 2006. During that interim period, the 
federal government created the Medicare Discount Drug Card Program. One stated goal of this 
program was to aid Medicare recipients in receiving lower prices for their prescriptions. Thus, 
MMA may have influenced both pharmaceutical prices and utilization before Part D took effect 
in 2006. In addition, if the optimal price for a drug was going to change significantly upon the 
initiation of Part D, a manufacturer may have wanted to adjust the drug’s price gradually over 
time so as to avoid the publicity associated with a sharp price change. We therefore use 2003 as 
our base year when estimating the effect of the program.
We focus initially on the top 1,000 drugs in the IMS data according to their 2003 sales, which 
account for 97 percent of the $196 billion in total sales in that same year. We then drop over-the-
counter (OTC) drugs and generics,18 although we later control for the presence of generic com-
petition for the branded drugs in our sample. This exclusion leaves us with a sample of 693 drugs 
17 Recall that Medicare did cover the cost for certain prescription drugs, such as cancer treatments, in this time 
period.
18 Of the top 1,000 products, 113 were available over the counter in 2006; these drugs would not be covered by 
Medicare Part D plans and would also rarely appear in the MEPS Prescribed Medicines file that we use to construct 
Medicare market shares. We next drop the 194 remaining drugs that are generic, given that there will typically be many 
manufacturers for each of these drugs and firms would have significantly less pricing power.
Table 1—Source of Payment for Prescriptions in the 2003 MEPS
All Medicare All other
Average total paid per prescription (US$) 69.5 69.9 69.2
Percent paid out of pocket 44.9 50.9 40.5
Percent paid by private insurance 34.5 19.8 45.2
Percent paid by Medicaid 12.4 13.9 11.3
Percent paid by VA 3.3 5.8 1.5
Percent paid by Medicare 3.3 7.8 0.0
Percent paid by TRICARE 1.1 1.2 1.0
Percent paid by other insurance 0.5 0.5 0.5
Total number of prescriptions 298,293 129,990 168,303
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that currently or previously enjoyed patent protection, with these treatments accounting for 87 
percent of the $196 billion in 2003 spending in our IMS data. We then merge these IMS data 
on sales and utilization in each year from 2001 to 2006 to the MEPS data on Medicare market 
shares, with 125 of these 693 treatments dropped from our sample because they do not appear in 
the MEPS. 19 This leaves us with a sample of 568 drugs that account for 79 percent of total 2003 
IMS spending.
One limitation to our focus on the top-selling brand drugs in 2003 is that any drug introduced 
in 2004 or later or that was not in the top 1,000 sellers in 2003 will not be included in our analy-
ses. Additionally, generic drugs or drugs sold over the counter are not included in our sample. 
Thus, to the extent that Part D plans influenced the price or utilization of these other products, 
our main analyses of the top-selling brand drugs will not capture these effects.
D. identifying protected Classes and Therapeutic Substitutes
Our model predicts a different response to the program from both drugs in the protected 
classes and drugs without substantial therapeutic competition. To identify the former we rely on 
IMS drug classifications. To determine which drugs were the only treatments, or one out of just 
two in the therapeutic class, we consulted a list of top-selling drugs and link it to the US pharma-
copoeia and CMS therapeutic classes and FKDT.20 Recall, PDP are required to “cover” at least 
two drugs per class and at least one in each FKDT.
III.  Empirical Framework and Main Results
The IMS data described above provide us with total sales by product in each year from 2001 to 
2006. We can also estimate the number of daily doses for each product by dividing the total quan-
tity (in standardized units) in each year by the corresponding average number of  standardized 
units per daily dose in each year. This allows us to form an estimate of the average price per day 
for each product. We use these data to estimate specifications of the following type:
(1) ∆pj,2003–6 = α1 + β1mmSj,2003 + µ1Yrsj,2003 + δ1Anygenericj,2006 + ε1 j,2003,
(2) ∆Qj,2003–6 = α2 + β2mmSj,2003 + µ2Yrsj,2003 + δ2Anygenericj,2006 + ε2 j,2003,
with j indexing drugs and ∆pj,2003–6 (∆Qj,2003–6 ) equal to the change in price (quantity) for 
drug j from 2003 to 2006. As described above, we focus on this three-year change because the 
legislation that created Part D was enacted in December 2003, but plans did not start enrolling 
beneficiaries until January 2006.
The explanatory variable of particular interest in this specification is mmSj,2003, which repre-
sents our estimate of the Medicare market share for drug j using the MEPS Prescribed Medicines 
files from 2002 and 2003. This is defined to be equal to the fraction of prescriptions filled in 
2002 and 2003 for individuals who were ever enrolled in the program during the same year.21 
This specification, which uses one observation per drug, exploits the variation across drugs in 
their tendency to be used by Medicare recipients. Given that total utilization and average prices 
19 There are two plausible reasons for this. First, MEPS does not include prescriptions that are administered in a 
physician’s office or other institutional setting. Second, MEPS captures approximately 1 out of every 10,000 prescrip-
tions in a typical year and thus some products with small patient populations may not be included.
20 One version of this can be found at http://www.usp.org/pdf/EN/mmg/drugListTableV3.0.pdf. 
21 In calculating this Medicare market share, we use the person weights in the MEPS. 
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for the same drug may vary over the life cycle of the drug and can be affected by the presence of 
generic competition, we also control for the number of years that the drug has been on the market 
(Yrsj,2003) and for whether the drug faces generic competition (Anygenericj,2006).22
It is worth noting that average prices tend to move fairly steadily in our data, and tend to trend 
up. In contrast, average quantities fluctuate much more due to the entry of therapeutic substitutes, 
new generations of medicines, clinical news, and other factors we do not observe. Additionally, 
average quantities in our sample decline from 2003 to 2006, primarily because we restrict atten-
tion to drugs that were the top sellers in 2003.
To interpret our estimates for β1 and β2 as the causal effects of Medicare Part D on the out-
come variable of interest, we are assuming that there are no omitted factors that are correlated 
with the Medicare market share, and that also influence the change in the outcome variable of 
interest.23 Over the short period of this study, that assumption seems reasonable to us. By taking 
first differences of average prices or total utilization, we remove any unobserved time-invariant 
differences across drugs.
A. The impact on Average prices
An examination of the distribution of average price and the change in average prices for the 
drugs in our analysis sample reveals that they are highly skewed to the right. For example, the 
change in the average price from 2003 to 2006 for the drugs in our sample has a skewness of more 
than 12. Thus, following recent research on pharmaceutical prices (Duggan and Scott Morton 
2006), we take the log of the average price, which is much more symmetrically distributed and 
has a skewness of approximately zero.24 This has intuitive appeal as well, as prices are likely to 
change proportionally rather than by a fixed dollar amount in response to common factors that 
affect prices in this sector. With this transformation, we are essentially exploring whether the 
growth rate of pharmaceutical prices is significantly different on average for Medicare-intensive 
drugs following the enactment of Part D.
Table 2 summarizes the results from several specifications similar to equation (1) above. In 
this equation, we exclude 20 of the 568 drugs described above because they either have no sales 
in 2006 or are missing the year of FDA approval. We weight the observations in each specifica-
tion by the number of prescriptions in the MEPS to account for the fact that the precision of our 
estimate for mmSj will vary across drugs. The estimate of −0.128 for β1 in the first column, in 
which no other explanatory variables except a constant are included, suggests that the introduc-
tion of Part D reduced the growth rate of pharmaceutical prices by an average of approximately 
12 percentage points, with this estimate significant at the 5 percent level. However, because the 
coefficient on the constant term α1 is equal to 0.134, this finding suggests that average prices for 
Medicare Part D recipients remained essentially unchanged, while those for other consumers 
increased by an average of 13 percent. Our estimates indicate that a drug moving from zero to 
100 percent MMS would have price growth drop from 13 percent to 1 percent.
22 As demonstrated in a previous version of this paper (Duggan and Scott Morton 2008), our results for both price 
and quantity changes are similar if we control for the preexisting trend for the outcome variable of interest.
23 In this paper we will not consider insurance-induced changes in practice patterns of physicians, the introduction 
of new drugs, and similar general equilibrium effects, as is done in Daron Acemoglu et al. (2006), Amy Finkelstein 
(2007), and Amy Finkelstein and Robin McKnight (2008), in which the authors looks at the effect of the introduction 
of Medicare. See also David Cutler (1995) and Leemore Dafny (2005) for related research on the effect of other impor-
tant changes to the Medicare program, or David Card, Carlos Dobkin, and Nicole Maestas (2008) and Ahmed Khwaja 
(2008) for research on the effect of Medicare coverage.
24 We inflation-adjust 2003 prices to 2006 dollars using the consumer price index for urban consumers (CPI-U).
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The magnitude of our estimate for β1 is almost identical, at −0.127 in the next specification, in 
which we add the control variables described above. This estimate increases slightly to −0.138 
and remains significant at the 5 percent level in the third specification, in which we exclude outli-
ers that are in the top 1 percent or bottom 1 percent of the log price change (from 2003 to 2006) 
distribution.
The MEPS Prescribed Medicines files do not include information for drugs administered in 
a physician’s office or clinic. The most common are injectable chemotherapy treatments. One 
might therefore be concerned that estimates for the Medicare market share for the cancer drugs 
that are in the sample are inaccurate. In the fourth specification we exclude these 21 treatments 
and obtain a very similar estimate for β1.
One potential concern with our estimate for the Medicare market share is that it weights 
all prescriptions equally. We therefore introduce an alternative measure of the Medicare mar-
ket share in the fifth specification which represents the fraction of total spending on the drug 
accounted for by Medicare recipients. The statistically significant estimate of −0.133 for β1 
using this measure is virtually identical to the previous estimates. In the next specification we 
consider only the top 200 drugs, as we did in our previous work for the Medicaid program, and 
find that our estimate for β1 increases to −0.143 and is significant at the 1 percent level.
Taken together, our results indicate that average prices increased by significantly less from 
2003 to 2006 for drugs sold differentially to Medicare recipients. When interpreting these 
estimates, it is important to consider that many Medicare recipients already had insurance for 
Table 2—The Impact of Medicare Part D on the Change in Average Pharmaceutical Prices from 2003–2006
Dependent variable: Δ log(price per dayj,2003–6)
μ (σ) (1) (2) (3) (4) (5) (6)
Medicare market share2002–03 0.348 −0.128** −0.127** −0.138** −0.136** −0.133** −0.143***
(0.264) (0.057) (0.057) (0.056) (0.056) (0.056) (0.054)
Years on the market2003 10.95 0.000 0.001 0.001 0.001 0.002
(7.36) (0.002) (0.002) (0.002) (0.002) (0.002)
Any generic competition 0.381 0.005 0.010 0.010 0.011 −0.008
(0.486) (0.023) (0.023) (0.023) (0.023) (0.022)
Constant — 0.134 0.128 0.127 0.126 0.125 0.127
— (0.026) (0.028) (0.028) (0.028) (0.028) (0.032)
Observations 548 548 548 538 517 517 200
R2 — 0.016 0.016 0.024 0.024 0.024 0.049
Outliers excluded? No No No Yes Yes Yes Yes
Cancer drugs excluded? No No No No Yes Yes Yes
RX or spending MMS? RX RX RX RX RX Spending RX
Top 200 only No No No No No No Yes
Notes: Each column summarizes the results from specifications of the change in the log price per daily dose on the 
explanatory variables listed in the first column. The unit of observation is the drug, and the sample is constructed as 
described in Section IIC. Specifications 1 through 4 and specification 6 use the share of a drug’s prescriptions pur-
chased by Medicare-enrolled individuals, while specification 5 uses the share of spending for that drug. Specifications 
3 through 6 drop those observations with values of the dependent variable in the top 1 percent or the bottom 1 percent 
of the distribution.  Specifications 4 through 6 exclude 21 cancer and immunosuppressant drugs. Specification 6 limits 
to just the top 200 drugs. Heteroskedasticity-robust standard errors are included in parentheses. The mean and standard 
deviation of the dependent variable are equal to 0.087 and 0.349, respectively.
*** Significant at the 1 percent level.
 ** Significant at the 5 percent level.
  * Significant at the 10 percent level.
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 prescription drug costs prior to the enactment of Medicare Part D. To the extent that the price 
effects were driven only by those enrolling in Part D plans, the estimates for β1 will understate 
Part D’s average impact on pharmaceutical prices. We explore this issue in more detail below.
B. The impact of part d on the utilization of prescription drugs
Medicare Part D reduced the out-of-pocket price of pharmaceutical treatments beyond the 
effects discussed above through an additional channel—the mechanical effect of the insurance 
coverage. For example, the typical plan in 2006 covered 75 percent of the first $2,000 in pre-
scription drug costs once a person had reached their annual deductible of $250. Additionally, 
Medicare recipients enrolled in Part D pay just 5 percent of their costs once their out-of-pocket 
spending reaches $3,600. Because Part D reduced both the gross price of prescription drugs and 
the share of that price paid by Medicare recipients, one would expect average utilization of these 
treatments to have increased.
To investigate the effect of Part D on the total utilization of prescription drugs, in this section 
we estimate quality specifications that are analogous to those in the preceding section for prices. 
In this case, the dependent variable is equal to the change in the log of the number of daily doses 
from 2003 to 2006, with the mean and standard deviation of this variable in the sample equal to 
−0.62 and 1.12, respectively.25
The results from these specifications are summarized in Table 3. The estimate of 0.516 for β2 
in the first specification, in which only the Medicare market share and a constant are included, 
is positive but statistically insignificant, with a p-value of 0.108. In the next specification, we 
include the number of years that the drug had been on the market as of 2003 and a control for the 
presence of generic competition. The estimates for the coefficients on the first of these variables 
is statistically  insignificant, while the estimate for δ2, the coefficient on Anygenj,2006, is signifi-
cantly negative with a t-statistic of −5.5. This is consistent with previous evidence that use of 
branded drugs declines substantially once they face generic competition. The estimates of β2 in 
the next five columns, which summarize specifications analogous to those for price changes, are 
similar in magnitude, although in all cases the estimates are statistically insignificant.
The large estimates for δ2 in specifications two through six of Table 3 suggest that utilization 
changes among drugs that face generic competition are substantially different from those that 
do not. To increase the comparability of the drugs included in our sample, in specification 7 we 
focus on just the 318 drugs in our sample that did not face generic competition by 2006. While 
smaller in magnitude than the previous estimates, the estimate of 0.265 for β2 in this specifica-
tion is significant at the 10 percent level.
To gauge the plausibility of these results, it is instructive to obtain a back-of-the-envelope 
estimate of the implied elasticity of prescription drug purchases for the 318 drugs in our sample. 
For a Medicare recipient with average prescription drug spending, the effective co-pay would 
be 25 percent. Adding to this a 12 percent average reduction in gross prices suggests almost an 
80 percent reduction in the out-of-pocket cost on the margin for purchases in the coverage area. 
Combining this with the estimated effect on utilization in column (7), our results suggest an 
elasticity of approximately −0.38, which falls within the range of drug elasticity estimates from 
other contexts cited in a recent review article (Gibson et al., 2005).
25 Utilization is on average declining because we are focusing on top-selling drugs in 2003. Many of these treat-
ments will have seen declines in spending in the subsequent three years.
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IV.  Heterogeneity in Part D’s Impact on Pharmaceutical Prices and Utilization
A. differentiating between insured and uninsured medicare Recipients
We begin this section by investigating whether the price effects estimated above also vary 
with the baseline insurance coverage of Medicare recipients. The shift from being uninsured into 
a Part D plan may have affected prices by placing individuals paying with cash into a large group 
that could bargain over prices, increasing their effective sensitivity to price differences. Second, 
the dual eligibles enrolled in both Medicare and Medicaid were required to switch from Medicaid 
drug coverage to a Medicare Part D plan. As recent research has demonstrated (Duggan and 
Scott Morton 2006), the procurement rules used by Medicaid distort prices upward, suggesting 
that a shift out of Medicaid may have reduced prices.
The specifications summarized in Table 4 shed light on this issue. In column 1, we report 
the results from our baseline specification that excluded the 21 cancer and 10 outlier treatments 
and was summarized in the preceding section. Column 2 presents the results from an analogous 
specification in which we differentiate between the Medicare self-pay and Medicare insured 
market shares as follows:
Table 3—The Impact of Medicare Part D on the Change in RX Utilization from 2003 to 2006
Dependent variable: Δ log(daily dosesj,2003–06)
μ (σ) (1) (2) (3) (4) (5) (6) (7)
Medicare market 0.348 0.516 0.434 0.381 0.389 0.321 0.517 0.265*
 share2002–03 (0.264) (0.320) (0.320) (0.313) (0.316) (0.313) (0.470) (0.137)
Years on the market 10.95 −0.004 −0.001 −0.001 −0.001 0.007 −0.023***
(7.36) (0.010) (0.011) (0.011) (0.011) (0.017) (0.007)
Any generic 0.381 −1.072*** −1.084*** −1.087*** −1.088*** −1.199***
 competition? (0.486) (0.191) (0.191) (0.192) (0.193) (0.243)
Constant — −0.826 −0.251 −0.228 −0.235 −0.208 −0.292 0.001
(0.161) (0.169) (0.164) (0.164) (0.166) (0.246) (0.112)
Observations 548 548 548 538 517 517 200 318
R2 — 0.009 0.262 0.293 0.294 0.293 0.318 0.108
Outliers excluded? No No No Yes Yes Yes Yes Yes
Cancer drugs excluded? No No No No Yes Yes Yes Yes
RX or spending MMS? RX RX RX RX RX Spending RX RX
Top 200 only No No No No No No Yes No
Exclude if face gen comp? No No No No No No No Yes
Notes: Each column summarizes the results from specifications of the change in the log number of daily doses on 
the explanatory variables listed in the first column. The unit of observation is the drug. and the sample is constructed 
as described in Section IIC. Specifications 1 through 4 and specifications 6 and 7 use the share of a drug’s prescrip-
tions purchased by Medicare-enrolled individuals, while specification 5 uses the share of spending for that drug. 
Specifications 3 through 7 drop those observations with values of the dependent variable in the top 1 percent or the 
bottom 1 percent of the distribution. Specifications 4 through 7 exclude 20 cancer and immunosuppressant drugs. 
Specification 6 limits to just the top 200 drugs and specification 7 considers only those sample drugs that do not face 
generic competition. Heteroskedasticity-robust standard errors are included in parentheses. The mean and standard 
deviation of the dependent variable are equal to −0.56 and 1.13, respectively.
*** Significant at the 1 percent level.
 ** Significant at the 5 percent level.
  * Significant at the 10 percent level.
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(3) ∆Yj,2003–6 = α + β1mmS_Selfj,2003 + β2mmS_insj,2003 + µYrsj,2003 
 + δ1Anygenericj,2006 + εj,2003,
in which Y is the outcome variable, price, or quantity. The average values for the two Medicare 
explanatory variables in our sample of 517 drugs are 0.217 and 0.135, respectively, and the latter 
share variable includes both private and public insurance.
The estimates for β1 and β2 displayed in column 2 suggest that the price effects of Medicare 
Part D do vary with a particular drug’s level of pre–Part D insurance coverage on the part of 
Medicare recipients. More specifically, the estimate of −0.225 for β1 implies that the average 
(gross) price of prescription drugs consumed by uninsured Medicare recipients fell by more 
than 20 percent from 2003 to 2006 relative to other drugs, and this estimate is significant at the 
1 percent level. The magnitude of the corresponding estimate for β2 has the opposite sign and is 
statistically insignificant. This suggests that the relative price declines observed for Medicare-
intensive drugs were driven by declines for drugs consumed disproportionately by beneficiaries 
previously without prescription drug coverage. Additionally, because the estimate of 0.115 for the 
constant α1 is smaller in magnitude than our estimate of −0.225 for β1, our results suggest that 
Medicare recipients’ average prices declined by approximately 10 percent in real terms while 
those for other consumers increased by 12 percent.
Table 4—The Impact of Medicare Market Share: Differentiating between Those with and  
without RX Insurance
Δ log(price per dayj,2003–06) Δ log(daily dosesj,2003–06)
Δ log(total
revenues j,2003–06)
μ (σ) (1) (2) (3) (4) (5) (6) (7) (8)
Medicare market 0.345 −0.136** 0.389 0.273
 share2002–03 (0.262) (0.056) (0.316) (0.314)
Medicare self-pay 0.213 −0.225*** −0.243*** 0.461 0.379 0.247
 share2002–03 (0.191) (0.070) (0.077) (0.424) (0.449) (0.438)
Medicare insured 0.132 0.059 0.232 0.330
 share2002–03 (0.134) (0.156) (0.881) (0.860)
Dual eligible 0.043 −0.182 −0.914
 share2002–03 (0.076) (0.274) (1.674)
Other medicare 0.089 0.190 0.850
 insured share2002–03 (0.107) (0.305) (1.216)
Years on the 10.9 0.001 0.001 0.001 −0.001 −0.001 −0.001 −0.002 −0.002
 market (7.3) (0.002) (0.002) (0.002) (0.011) (0.011) (0.011) (0.011) (0.011)
Any generic 0.385 0.010 0.011 0.010 −1.087*** −1.088*** −1.096*** −1.071*** −1.071***
 competition (0.487) (0.023) (0.023) (0.023) (0.192) (0.193) (0.194) (0.187) (0.187)
Constant — 0.126 0.115 0.118 −0.235 −0.226 −0.211 −0.107 −0.111
— (0.028) (0.030) (0.028) (0.164) (0.180) (0.179) (0.164) (0.178)
Observations 517 517 517 517 517 517 517 517 517
R2 — 0.024 0.027 0.033 0.294 0.294 0.297 0.293 0.293
Notes: Specifications 1 through 3, 4 through 6, and 7 through 8 summarize the results from specifications of the change in the log price 
per daily dose, the log number of daily doses, and the log of product revenues, respectively, that use the explanatory variables listed in 
the first column. The unit of observation is the drug, and the sample is constructed as described in Section IIC. All eight specifications 
use the share of a drug’s prescriptions purchased by Medicare-enrolled individuals as the measure of Medicare market share, drop those 
observations with values of the dependent variable in the top 1 percent or the bottom 1 percent of the distribution, and exclude the 20 
cancer and immunosuppressant drugs. Heteroskedasticity-robust standard errors are included in parentheses.
*** Significant at the 1 percent level.
 ** Significant at the 5 percent level.
  * Significant at the 10 percent level.
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In the next specification summarized in column 3, we differentiate between Medicare recipi-
ents also enrolled in Medicaid and those with an alternative source of insurance. Given the price 
distortions created by Medicaid’s procurement rules, one might expect the movement of duals 
into Part D to cause a reduction in private market prices. If so, we will see price reduction associ-
ated with a drug’s dual share, rather than its MMS. The estimate of −0.182 for the coefficient on 
the dual eligible share is consistent with this hypothesis, although it is not statistically significant. 
Furthermore, the estimate of −0.243 for β1 remains of similar magnitude and is statistically 
significant at the 1 percent level. We thus conclude that the movement of duals is not responsible 
for the effect we measure.
In the next three columns of this table, we summarize the results from an analogous set of 
specifications for the utilization (in terms of the log of the number of daily doses) of the 517 drugs 
in our sample. To the extent that the enactment of Part D reduced the net cost of prescription 
drugs by more for uninsured Medicare recipients than for their counterparts who already had 
insurance, one would expect a larger increase in utilization for drugs consumed by this group. 
Consistent with this, the estimate of 0.461 for β1 in specification 5 is almost twice as large as 
the corresponding estimate for β2, though given the large standard errors the difference is not 
statistically significant.
The results in the final columns investigate the effect of Part D on total US revenues. Given 
that Part D reduced pharmaceutical prices below what they otherwise would have been while 
increasing the quantity consumed, it is theoretically ambiguous whether the revenues of pharma-
ceutical products increased or declined as a result of this legislation. The estimate of 0.273 for 
β1 in column 7 suggests an increase in revenues for Medicare-intensive drugs, though it is not 
statistically significant.
Taken together, the results presented in this section suggest that Medicare Part D led to 
smaller price increases than would otherwise have occurred for Medicare recipients who 
lacked insurance coverage for prescription drug costs, which is the group most likely to have 
enrolled in Part D plans. We find little evidence to suggest that there was a corresponding 
effect on the price of drugs sold differentially to Medicare recipients who already had pre-
scription drug coverage.
B. protected Therapeutic Categories
While private firms providing Part D benefits had considerable latitude in designing their 
formularies, they were required to cover at least two treatments in each eligible therapeutic 
 category. This requirement was introduced to reduce plans’ ability to “cream skim” the least 
costly patients by excluding treatments for certain conditions. However, the ability to exclude 
certain treatments from the formulary provides plans with potentially important leverage when 
negotiating prices with pharmaceutical manufacturers.
The Part D requirements were substantially more stringent for a small subset of the 146 thera-
peutic categories defined by CMS. Specifically, plans were required to cover “substantially all” 
drugs in the following six therapeutic categories: antiretrovirals, antidepressants, antipsychotics, 
anticonvulsants, immunosuppressants, and antineoplastics. Part D plans could still try to steer 
patients toward certain treatments within these categories through differential co-pays, prior 
authorization requirements, or step therapy. However, plans were restricted in their use of utiliza-
tion tools in the protected classes.
Thus, all else equal, a plan’s leverage in negotiating low prices for drugs in these six protected 
categories would be less than if it could exclude the drug altogether. The same would be true for 
categories with just one or two available treatments. Note that this group of drugs is therefore 
missing one of the two effects we discussed above: while the impact of insurance increasing 
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optimal prices is present, the offsetting effect of therapeutic competition among substitutes is 
likely to be very weak.
To investigate whether the price effects of Medicare Part D were different for protected classes 
or for classes with just one or two treatments, we estimate specifications of the following type:
(4) ∆Yj,2003–6 = α + βmmSj,2003 + λprotj + σmmSj,2003 protj + µSmall
  + ρmmSj,2003 Smallj + εj,2003.
In this equation, protj is set equal to one if drug j is in one of the protected categories, and is oth-
erwise set equal to zero. Similarly, Smallj is set equal to one if drug j is in a therapeutic category 
with just one or two available treatments. Both variables are interacted with the Medicare market 
share to explore whether the average price effects differ for drugs in this category. To the extent 
that Part D plans were less successful at negotiating price reductions in these two categories, one 
would expect positive estimates for σ and ρ.
The results summarized in Table 5 shed light on this prediction. In the first three columns 
we include all 517 drugs in the sample, with 48 of these treatments falling into one of the six 
protected classes, and 22 of them belonging to a category with just one or two available treat-
ments. In the first specification we add only the protj indicator and its interaction with mmSj to 
our baseline specification. Consistent with our prediction, our estimate for σ is positive and at 
0.175 is larger in magnitude than the estimate of −0.141 for β. However, this estimate for σ is not 
statistically significant. Standard errors are clustered by therapeutic subcategory given that the 
protected class indicator varies at this level.
In the specification summarized in the next column, we add the indicator for being in a “small” 
therapeutic category and its interaction with the Medicare market share to our baseline specifica-
tion. Consistent with our theoretical predictions, the estimate for the coefficient on the interac-
tion variable is positive and statistically significant at the 10 percent level. The magnitude of this 
estimate of 0.304 is more than twice as large as the main effect estimate of −0.142, suggesting 
that, if anything, Medicare-intensive treatments in the “small” categories experienced average 
price increases relative to other drugs.
These findings for price effects are similar when we include both indicators and their interac-
tions with the Medicare market share in specification three, and becomes significant at the five 
percent level when we focus only on treatments without generic competition (column 4). Taken 
together, our results suggest that Medicare Part D did not lead to lower price increases for treat-
ments in the “small” therapeutic categories.
The next four columns report the results from an analogous set of specifications for the utiliza-
tion measure defined above. In specifications five, six, and seven, the estimate for both σ and ρ 
are significantly negative, suggesting that Medicare-intensive drugs in protected classes and in 
classes with just one or two treatments experienced decreases in utilization following the enact-
ment of Part D. The first of these two estimates becomes small in magnitude and statistically 
insignificant in specification eight, where we focus on just treatments that do not face generic 
competition. However, the significant negative estimate for ρ remains, suggesting that perhaps 
Part D plans shifted recipients away from treatments in these “small” categories. While the 
CMS formulary discourages such shifting, plans are permitted to develop differentiated formu-
laries, provided they can justify their choices to CMS as both providing sufficient quality, and 
not attempting to cream-skim. The combination of results suggests that brands given market 
power by the CMS formulary raised their prices and saw some market share losses due to Part D 
formulary design. However, because our quantity results are generally imprecise, we do not put 
emphasis on this explanation.
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V.  Discussion
The introduction of Medicare Part D is arguably the most significant change to the Medicare 
program since its inception more than 40 years ago. The procurement rules that are used by 
Part D differ substantially from those used by Medicare for other health care services, by the 
federal-state Medicaid program, or by the US Department of Veterans Affairs for prescription 
drugs. One of the central criticisms of Part D was that it would lead to significant increases in 
pharmaceutical prices, to some extent offsetting the benefit of the additional insurance coverage.
In this paper, we investigate this issue using price, quantity, and sales data for the top-selling 
branded pharmaceutical treatments in the United States for the period before the enactment of 
Medicare Part D and in the one year immediately following. We combine this with information 
on the insurance coverage of each brand’s consumers, which allows us to compare price and 
utilization changes as a function of each treatment’s baseline Medicare market share. Our find-
ings strongly suggest that Part D plans have succeeded in negotiating lower price increases for 
Part D enrollees —approximately 20 percent lower than they otherwise would have been—with 
this effect augmenting the mechanical effect of the program in reducing out-of-pocket prices. 
Our findings also suggest, consistent with recent research (e.g., Lichtenberg and Sun 2007), that 
Part D has increased the utilization of pharmaceutical treatments.
In contrast to the usual intuition that the uninsured customer is the most price-sensitive, we 
find that the insured customer is more price-elastic. The most plausible explanation is that in 
Part D, insurance is bundled with group purchasing and the implementation of a formulary. The 
Table 5—The Impact of Medicare Market Share: Variation across Therapeutic Categories
Δ log(price per dayj,2003–06) Δ log(Daily Dosesj,2003–06)
(1) (2) (3) (4) (5) (6) (7) (8)
Medicare market sharej,2002–03 −0.141** −0.142** −0.147** −0.173** 0.527* 0.429 0.572* 0.345**
(0.059) (0.057) (0.061) (0.080) (0.299) (0.315) (0.310) (0.147)
Protected −0.042 −0.043 −0.029 1.027* 1.048** 0.102
(0.071) (0.055) (0.073) (0.497) (0.498) (0.156)
Protected × mmSj,2002–03 0.175 0.174 0.173 −3.610** −3.655** −0.030
(0.192) (0.200) (0.151) (1.662) (1.669) (0.355)
Small category −0.083 −0.083 −0.103* 0.712*** 0.740*** 0.631***
(0.058) (0.058) (0.058) (0.212) (0.212) (0.171)
Small category × mmSj,2002–03 0.304* 0.303* 0.366** −1.252** −1.272** −1.151**
(0.155) (0.154) (0.163) (0.542) (0.577) (0.454)
Years on the market 0.001 0.001 0.001 0.003 −0.001 −0.001 −0.001 −0.023***
(0.002) (0.002) (0.002) (0.003) (0.008) (0.008) (0.008) (0.007)
Any generic competition 0.010 0.012 0.011 −1.095*** −1.074*** −1.082***
(0.024) (0.023) (0.024) (0.248) (0.232) (0.249)
Constant 0.127 0.127 0.128 0.119 −0.278 −0.270 −0.317 −0.054
(0.029) (0.031) (0.032) (0.042) (0.140) (0.146) (0.144) (0.117)
Observations 517 517 517 318 517 517 517 318
R2 0.025 0.026 0.028 0.059 0.315 0.297 0.319 0.131
Exclude if face gen comp? No No No Yes No No No Yes
Notes: Specifications 1 through 4 and 5 through 8 summarize the results from specifications of the change in the log price per daily 
dose and in the log number of daily doses, respectively, that use the explanatory variables listed in the first column. The unit of obser-
vation is the drug, and the sample is constructed as described in Section IIC. All eight specifications use the share of a drug’s pre-
scriptions purchased by Medicare-enrolled individuals as the measure of Medicare market share. All eight specifications drop those 
observations with values of the dependent variable in the top 1 percent or the bottom 1 percent of the distribution and exclude the 20 
cancer and immunosuppressant drugs. Specifications 4 and 8 drop those treatments that face generic competition in 2006 or earlier. 
Heteroskedasticity-robust standard errors are included in parentheses.
*** Significant at the 1 percent level.
 ** Significant at the 5 percent level.
  * Significant at the 10 percent level.
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PDP’s ability to obtain lower prices indicates that a significant benefit of the program is the way 
it is organized, regardless of the subsidy level. Our evidence indicates that the PDP’s ability to 
encourage the use of therapeutic substitutes by a large group outweighs the classic insurance-
induced increases in pharmaceutical prices, and therefore leads to relative price declines for 
brands. It is perhaps partly because of the price effects estimated in this paper that Part D expen-
ditures by the federal government have been substantially lower than the most widely cited esti-
mates suggested (CMS 2007b). Furthermore, our results provide an example of the more general 
point that including the uninsured in a large group with the ability to select providers may greatly 
reduce costs even in the absence of a government subsidy.
When interpreting the results in this paper, a number of caveats should be mentioned. First 
and most important, given the available data, we can investigate the effect of Part D only in its 
first year. To the extent that plans become more or less successful at negotiating prices in future 
years, the results may of course change. Second, we are unable to measure any ex post rebates 
that PDPs may have been able to negotiate and that affect net prices to PDPs. Such rebates do not 
appear on the invoice, which is the source of IMS data, and might be causing prices to be even 
lower than those measured here. The other rebates that we do not measure are Medicaid rebates 
paid by manufacturers to the Medicaid program. Dual eligibles’ pharmaceutical purchases under 
Medicaid automatically generated this rebate. Once dual eligibles move into Medicare Part D 
plans, their pharmaceutical purchases occur at different prices, which is what we document here, 
but they no longer trigger automatic rebates. Any study of the total cost of Part D to the govern-
ment would want to consider both sets of rebates. Third, our results do not shed light on the effect 
of the program on the health of enrollees nor on their ability to smooth consumption in response 
to adverse health shocks. And, finally, we have not considered the effect of Part D on innovation, 
as this is a long-run outcome. However, to the extent that Part D reduces prices for drugs that 
have close substitutes rather than for drugs that do not have substitutes, we would conjecture that 
Part D increases the incentives for firms to invent novel treatments. All of these issues remain 
important areas for future research.
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